Results 31 to 40 of about 142,846 (219)

Impact of cryopreservation on CAR T production and clinical response

Frontiers in Oncology, 2022
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies.
Karin Brezinger-Dayan, Orit Itzhaki, Jenny Melnichenko, Adva Kubi, Li-at Zeltzer, Elad Jacoby, Elad Jacoby, Abraham Avigdor, Ronnie Shapira Frommer, Michal J. Besser, Michal J. Besser, Michal J. Besser   +11 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

BMC Cancer, 2020
Background More favorable treatment against epithelial ovarian cancer (EOC) is urgently needed because of its insidious nature at an early stage and a low rate of five-year survival.
Tong Li, Jiandong Wang
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects

Cell Reports Medicine
Summary: Transforming growth factor (TGF)-β1 restricts the expansion, survival, and function of CD4+ T cells. Here, we demonstrate that CD4+ but not CD8+ anti-TGF-β CAR T cells (T28zT2 T cells) can suppress tumor growth partly through secreting Granzyme ...
Diwei Zheng, Le Qin, Jiang Lv, Meihui Che, Bingjia He, Yongfang Zheng, Shouheng Lin, Yuekun Qi, Ming Li, Zhaoyang Tang, Bin-Chao Wang, Yi-Long Wu, Robert Weinkove, Georgia Carson, Yao Yao, Nathalie Wong, James Lau, Jean Paul Thiery, Dajiang Qin, Bin Pan, Kailin Xu, Zhenfeng Zhang, Peng Li   +22 more
doaj   +1 more source

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma

Frontiers in Immunology
BackgroundChimeric antigen receptor T (CAR-T) cell therapy is more effective in relapsed or refractory diffuse large B cell lymphoma (DLBCL) than other therapies, but a high proportion of patients relapse after CAR-T cell therapy owing to antigen escape,
Zhi Guo, Zhi Guo, Mingxin He, Ning Liu, Yiqing Yang, Rui Sun, Jianxun Wang, Qiang Wang   +7 more
doaj   +1 more source

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Scientific Reports, 2022
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to
Li Li, Qing Li, Zi-Xun Yan, Ling-Shuang Sheng, Di Fu, Pengpeng Xu, Li Wang, Wei-Li Zhao   +7 more
doaj   +1 more source

The Shewanella oneidensis Fic enzyme SoFic targets the switch‐I region of EF‐Tu for AMPylation

FEBS Letters, EarlyView.
Fic enzymes mediate diverse post‐translational modifications across all domains of life, including AMPylation. Prokaryotic EF‐Tu can be AMPylated and deAMPylated by the conserved Fic enzyme SoFic. Structural and biochemical approaches were used to characterize the effect of AMPylation on EF‐Tu, SoFic's enzymatic activities, and the enzyme‐target ...
Svenja Runge, Vivian Pogenberg, Alexander Baumgart, Bente Siebels, Hartmut Schlüter, Michael Hecht‐Bucher, Aymelt Itzen   +6 more
wiley   +1 more source

IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma

Frontiers in Immunology, 2023
Chimeric antigen receptor (CAR) T cell therapy in glioblastoma faces many challenges including insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, preclinical studies evaluating CAR T cells in glioblastoma
Sheridan L. Swan, Nalini Mehta, Ekaterina Ilich, Steven H. Shen, Steven H. Shen, Steven H. Shen, Daniel S. Wilkinson, Alexa R. Anderson, Tatiana Segura, Tatiana Segura, Luis Sanchez-Perez, Luis Sanchez-Perez, Luis Sanchez-Perez, John H. Sampson, John H. Sampson, John H. Sampson, John H. Sampson, Ravi V. Bellamkonda, Ravi V. Bellamkonda   +18 more
doaj   +1 more source